Analysis Group Researchers to Present at ISPE 2024
Event: 40th International Society for Pharmacoepidemiology (ISPE) Annual Meeting Dates: 25–29 August 2024 Host: International Society for Pharmacoepidemiology (ISPE) Location: Berlin, Germany
Analysis Group, a global leader in drug safety epidemiology and regulatory real-world evidence (RWE), will present two podium presentations and five research posters at the 40th annual meeting of the International Society for Pharmacoepidemiology (ISPE).
Vice President Marianne Cunnington is a coauthor of two podium presentations at the meeting:
Monday, August 26, 1:30 p.m. CEST, Convention Hall I D
- Applying the self-controlled case series to analyze safety endpoints in single-arm, open label extension studies: A case study of Belimumab for the treatment of systemic lupus erythematosus and risk of infection
Wednesday, August 28, 8:45 a.m. CEST, Room XV
- Impact of data source diversity on the distribution of key variables in pregnancy cohorts based on the ConcePTION pregnancy algorithm leveraging a random forest imputation model
Additionally, researchers from Analysis Group – including Managing Principals Mei Sheng Duh and Maral DerSarkissian; Vice Presidents Rose Chang, Marianne Cunnington, and Fan Mu; and Managers Catherine Nguyen and Erin Cook – will present five posters at the meeting on the following topics:
Poster Session A: Monday, August 26, 8:00 a.m.–6:00 p.m. CEST
- Poster No. 158: Comparative Effectiveness of ARB and ACEi for Cardiovascular Outcomes and Risk of Angioedema by Ethnicity: an Analysis in the UK Clinical Practice Research Datalink with Emulation of a Reference Trial (ONTARGET)
- Poster No. 108: Impact of Treatment of COVID-19 with Sotrovimab on Post-Acute COVID-19 Syndrome: An Analysis of National COVID Cohort Collaborative (N3C) Data
- Poster No. 070: NALIRIFOX versus FOLFOX as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall (OS) survival analysis
Poster Session B: Tuesday, August 27, 8:00 a.m.–6:00 p.m. CEST
- Poster No. 342: Final Results from Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
Poster Session C: Wednesday, August 28, 8:00 a.m.–1:30 p.m. CEST
- Poster No. 305: High Misclassification of Glycogen Storage Disease Type 1a in a US Electronic Medical Records Database – Insights from a Physician Note Review
Further details on the podium presentations and posters are available in our 2024 ISPE Presentation Guide. Analysis Group is a proud gold sponsor of this meeting.
Associated People
Marianne Cunnington
Vice PresidentDr. Cunnington has over 20 years of experience as a pharmaceutical industry epidemiologist. She specializes in the generation of real-world evidence (RWE) in support of the development and lifecycle management of pharmaceutical and vaccine products, with particular focus on regulatory risk management strategies and product benefit risk assessments. Dr. Cunnington focuses on regulatory epidemiology with design and execution of real-world post-marketing safety studies, as well as real-world studies to support the approval of new products in the context of innovative regulatory pathways. Her research expertise includes design, negotiation, and execution of real-world components of risk management plans for multiple new product submission with regulators across multiple geographies (US, UK, Europe, Japan, South Korea), post approval safety studies in the EU, post-marketing requirement and commitment studies in the US, and pregnancy registries. Prior to joining Analysis Group, Dr. Cunnington held several senior epidemiology positions within Novartis and GlaxoSmithKline (GSK). At GSK, she chaired the peer review forum for all pharmaceutical real world evidence projects, provided epidemiological expertise for the GSK’s Global Safety Board and was a managing board member of the Innovative Medicines Initiative’s public-private partnership, building an integrated European real-world data network to monitor medication safety in pregnancy. Dr. Cunnington is currently an elected board member representing European industry and service providers for the International Society of Pharmacoepidemiology.